About NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States as well as worldwide, with an estimated prevalence ranging from 25% to 40%. Nonalcoholic steatohepatitis (NASH) is the aggressive form of NAFLD that can progress to cirrhosis, liver failure, and hepatocellular carcinoma. NASH is also associated with substantial economic burden, inflicting $103 billion of direct medical costs each year in the United States.
Team
& Associate Professor, Harvard Medical School
and Professor of Medicine (with tenure) in the Division of Gastroenterology,
University of California at San Diego
at Massachusetts General Hospital
Director of the MGH Fatty Liver Clinic in the Gastroenterology and Hepatology Division
About The Simulator
NAFLD Simulator is an interactive, open-access tool that provides information on the short- and long-term risks associated with NAFLD and NASH. It provides patients and providers individualized risk predictions based on person’s risk and demographic factors. The Simulator also aims to increase the awareness of NASH by providing data on mortality and long-term consequences of NASH. The Simulator is based on a clinical-valid mathematical model that simulates the natural history of NAFLD. The outcomes of the mathematical model have been validated with three large observational studies. The tool allows users to enter patient demographics and current NAFLD stage, and predicts survival, mortality (liver, non-liver, and background), cumulative incidence of liver cancer and decompensated cirrhosis. The Simulator also allows users to compare outcomes between different NAFLD stages.
Visit our other sites
Contact
Jagpreet Chhatwal, PhD
MGH Inst. for Tech. Assessment
Harvard Medical School
101 Merrimac St. STE 1010
Boston, MA 02114 United States
JagChhatwal@mgh.harvard.edu
Acknowledgment
This work is supported by the American Association for the Study of Liver Diseases Innovation Fund
